Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients.
Development of direct acting antivirals (DAA) offers new benefits for patients with chronic hepatitis C. The combination of these drugs with antiretroviral treatment (cART) is a real challenge in HIV/HCV coinfected patients. The aim of this study was to describe potential drug-drug interactions betw...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4619009?pdf=render |
id |
doaj-6d5042d035404c1c817dc8b23c24e1e0 |
---|---|
record_format |
Article |
spelling |
doaj-6d5042d035404c1c817dc8b23c24e1e02020-11-25T01:31:38ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011010e014116410.1371/journal.pone.0141164Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients.Isabelle Poizot-MartinAlissa NaqviVéronique Obry-RoguetMarc-Antoine ValantinLise CuzinEric BillaudAntoine CheretDavid ReyChristine JacometClaudine DuvivierPascal PugliesePierre PradatLaurent CotteHepadat'AIDS Study GroupDevelopment of direct acting antivirals (DAA) offers new benefits for patients with chronic hepatitis C. The combination of these drugs with antiretroviral treatment (cART) is a real challenge in HIV/HCV coinfected patients. The aim of this study was to describe potential drug-drug interactions between DAAs and antiretroviral drugs in a cohort of HIV/HCV coinfected patients.Cross-sectional study of all HIV/HCV coinfected patients attending at least one visit in 2012 in the multicenter French Dat'AIDS cohort. A simulation of drug-drug interactions between antiretroviral treatment and DAAs available in 2015 was performed.Of 16,634 HIV-infected patients, 2,511 had detectable anti-HCV antibodies, of whom 1,196 had a detectable HCV-RNA and were not receiving HCV treatment at the time of analysis. 97.1% of these patients were receiving cART and 81.2% had a plasma HIV RNA <50 copies/mL. cART included combinations of nucleoside reverse transcriptase inhibitors with a boosted protease inhibitor in 43.6%, a non-nucleoside reverse transcriptase inhibitor in 17.3%, an integrase inhibitor in 15.4% and various combinations or antiretroviral drugs in 23.7% of patients. A previous treatment against HCV had been administered in 64.4% of patients. Contraindicated associations/potential interactions were expected between cART and respectively sofosbuvir (0.2%/0%), sofosbuvir/ledipasvir (0.2%/67.6%), daclatasvir (0%/49.4%), ombitasvir/boosted paritaprevir (with or without dasabuvir) (34.4%/52.2%) and simeprevir (78.8%/0%).Significant potential drug-drug interactions are expected between cART and the currently available DAAs in the majority of HIV/HCV coinfected patients. Sofosbuvir/ledipasvir and sofosbuvir/daclatasvir with or without ribavirin appeared the most suitable combinations in our population. A close collaboration between hepatologists and HIV/AIDS specialists appears necessary for the management of HCV treatment concomitantly to cART.http://europepmc.org/articles/PMC4619009?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Isabelle Poizot-Martin Alissa Naqvi Véronique Obry-Roguet Marc-Antoine Valantin Lise Cuzin Eric Billaud Antoine Cheret David Rey Christine Jacomet Claudine Duvivier Pascal Pugliese Pierre Pradat Laurent Cotte Hepadat'AIDS Study Group |
spellingShingle |
Isabelle Poizot-Martin Alissa Naqvi Véronique Obry-Roguet Marc-Antoine Valantin Lise Cuzin Eric Billaud Antoine Cheret David Rey Christine Jacomet Claudine Duvivier Pascal Pugliese Pierre Pradat Laurent Cotte Hepadat'AIDS Study Group Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients. PLoS ONE |
author_facet |
Isabelle Poizot-Martin Alissa Naqvi Véronique Obry-Roguet Marc-Antoine Valantin Lise Cuzin Eric Billaud Antoine Cheret David Rey Christine Jacomet Claudine Duvivier Pascal Pugliese Pierre Pradat Laurent Cotte Hepadat'AIDS Study Group |
author_sort |
Isabelle Poizot-Martin |
title |
Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients. |
title_short |
Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients. |
title_full |
Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients. |
title_fullStr |
Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients. |
title_full_unstemmed |
Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients. |
title_sort |
potential for drug-drug interactions between antiretrovirals and hcv direct acting antivirals in a large cohort of hiv/hcv coinfected patients. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
Development of direct acting antivirals (DAA) offers new benefits for patients with chronic hepatitis C. The combination of these drugs with antiretroviral treatment (cART) is a real challenge in HIV/HCV coinfected patients. The aim of this study was to describe potential drug-drug interactions between DAAs and antiretroviral drugs in a cohort of HIV/HCV coinfected patients.Cross-sectional study of all HIV/HCV coinfected patients attending at least one visit in 2012 in the multicenter French Dat'AIDS cohort. A simulation of drug-drug interactions between antiretroviral treatment and DAAs available in 2015 was performed.Of 16,634 HIV-infected patients, 2,511 had detectable anti-HCV antibodies, of whom 1,196 had a detectable HCV-RNA and were not receiving HCV treatment at the time of analysis. 97.1% of these patients were receiving cART and 81.2% had a plasma HIV RNA <50 copies/mL. cART included combinations of nucleoside reverse transcriptase inhibitors with a boosted protease inhibitor in 43.6%, a non-nucleoside reverse transcriptase inhibitor in 17.3%, an integrase inhibitor in 15.4% and various combinations or antiretroviral drugs in 23.7% of patients. A previous treatment against HCV had been administered in 64.4% of patients. Contraindicated associations/potential interactions were expected between cART and respectively sofosbuvir (0.2%/0%), sofosbuvir/ledipasvir (0.2%/67.6%), daclatasvir (0%/49.4%), ombitasvir/boosted paritaprevir (with or without dasabuvir) (34.4%/52.2%) and simeprevir (78.8%/0%).Significant potential drug-drug interactions are expected between cART and the currently available DAAs in the majority of HIV/HCV coinfected patients. Sofosbuvir/ledipasvir and sofosbuvir/daclatasvir with or without ribavirin appeared the most suitable combinations in our population. A close collaboration between hepatologists and HIV/AIDS specialists appears necessary for the management of HCV treatment concomitantly to cART. |
url |
http://europepmc.org/articles/PMC4619009?pdf=render |
work_keys_str_mv |
AT isabellepoizotmartin potentialfordrugdruginteractionsbetweenantiretroviralsandhcvdirectactingantiviralsinalargecohortofhivhcvcoinfectedpatients AT alissanaqvi potentialfordrugdruginteractionsbetweenantiretroviralsandhcvdirectactingantiviralsinalargecohortofhivhcvcoinfectedpatients AT veroniqueobryroguet potentialfordrugdruginteractionsbetweenantiretroviralsandhcvdirectactingantiviralsinalargecohortofhivhcvcoinfectedpatients AT marcantoinevalantin potentialfordrugdruginteractionsbetweenantiretroviralsandhcvdirectactingantiviralsinalargecohortofhivhcvcoinfectedpatients AT lisecuzin potentialfordrugdruginteractionsbetweenantiretroviralsandhcvdirectactingantiviralsinalargecohortofhivhcvcoinfectedpatients AT ericbillaud potentialfordrugdruginteractionsbetweenantiretroviralsandhcvdirectactingantiviralsinalargecohortofhivhcvcoinfectedpatients AT antoinecheret potentialfordrugdruginteractionsbetweenantiretroviralsandhcvdirectactingantiviralsinalargecohortofhivhcvcoinfectedpatients AT davidrey potentialfordrugdruginteractionsbetweenantiretroviralsandhcvdirectactingantiviralsinalargecohortofhivhcvcoinfectedpatients AT christinejacomet potentialfordrugdruginteractionsbetweenantiretroviralsandhcvdirectactingantiviralsinalargecohortofhivhcvcoinfectedpatients AT claudineduvivier potentialfordrugdruginteractionsbetweenantiretroviralsandhcvdirectactingantiviralsinalargecohortofhivhcvcoinfectedpatients AT pascalpugliese potentialfordrugdruginteractionsbetweenantiretroviralsandhcvdirectactingantiviralsinalargecohortofhivhcvcoinfectedpatients AT pierrepradat potentialfordrugdruginteractionsbetweenantiretroviralsandhcvdirectactingantiviralsinalargecohortofhivhcvcoinfectedpatients AT laurentcotte potentialfordrugdruginteractionsbetweenantiretroviralsandhcvdirectactingantiviralsinalargecohortofhivhcvcoinfectedpatients AT hepadataidsstudygroup potentialfordrugdruginteractionsbetweenantiretroviralsandhcvdirectactingantiviralsinalargecohortofhivhcvcoinfectedpatients |
_version_ |
1725085550920073216 |